Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza A and B virus infections in February 2018 in Japan. Because of the need to monitor influenza viruses for reduced susceptibility to this drug, we used two cell-based screening systems – a con...

Full description

Bibliographic Details
Main Authors: Emi Takashita, Hiroko Morita, Rie Ogawa, Kazuya Nakamura, Seiichiro Fujisaki, Masayuki Shirakura, Tomoko Kuwahara, Noriko Kishida, Shinji Watanabe, Takato Odagiri
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Microbiology
Subjects:
influenza virus
cap-dependent endonuclease inhibitor
baloxavir marboxil
baloxavir acid
S-033188
neuraminidase inhibitors
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2018.03026/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2018.03026/full

Similar Items